Evidence map›Paper›PMID 32258945›Full record

ReviewHepatology communications2020

Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes.

Michael J Weaver, Scott A McHenry, Gregory S Sayuk, C Prakash Gyawali, Nicholas O Davidson

Open access · goldAbstract readReview
In one paragraph

Review in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Intestinal secretory mechanisms and diarrhea.American journal of physiology. Gastrointestinal and liver physiology · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michael J WeaverDivision of Gastroenterology Washington University School of Medicine St. Louis MO.
Scott A McHenryDivision of Gastroenterology Washington University School of Medicine St. Louis MO.
Gregory S SayukDivision of Gastroenterology Washington University School of Medicine St. Louis MO.
C Prakash GyawaliDivision of Gastroenterology Washington University School of Medicine St. Louis MO.
Nicholas O DavidsonDivision of Gastroenterology Washington University School of Medicine St. Louis MO.
Washington University in St. Louis · USJohn Cochran VA Medical Center · US

Funding

Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8M
CLINICAL/LABORATORY TRAINING ACADEMIC GASTROENTEROLOGYT32DK007130 · NIDDK · WASHINGTON UNIVERSITY · PI MATTHEW AARON CIORBA · 1986 to 2026
$8.3M
ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESISR01HL038180 · NHLBI · WASHINGTON UNIVERSITY · PI DAVIDSON, NICHOLAS O. · 1986 to 2018
$3.8M
Impaired VLDL secretion, progression and reversal of hepatic fibrogenesisR01DK119437 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2019 to 2026
$3.8M
Bile acid metabolomics and metagenomics in short bowel syndromeR01DK112378 · NIDDK · WASHINGTON UNIVERSITY · PI DAVIDSON, NICHOLAS O., RUBIN, DEBORAH C. · 2016 to 2018
$1.1M
NHLBI NIH HHS R01 HL038180NIDDK NIH HHS P30 DK052574NIDDK NIH HHS R01 DK112378NIDDK NIH HHS R01 DK119437NIDDK NIH HHS T32 DK007130
6 · The paper itself

Abstract

Irritable bowel syndrome with diarrhea (IBS-D) and NAFLD are both common conditions that may be influenced by shared pathways of altered bile acid (BA) signaling and homeostatic regulation. Pathophysiological links between IBS-D and altered BA metabolism include altered signaling through the ileal enterokine and fibroblast growth factor 19 (FGF19) as well as increased circulating levels of 7α-hydroxy-4-cholesten-3-one, a metabolic intermediate that denotes increased hepatic BA production from cholesterol. Defective production or release of FGF19 is associated with increased BA production and BA diarrhea in some IBS-D patients. FGF19 functions as a negative regulator of hepatic cholesterol 7α-hydroxylase; therefore, reduced serum FGF19 effectively de-represses hepatic BA production in a subset of IBS-D patients, causing BA diarrhea. In addition, FGF19 modulates hepatic metabolic homeostatic response signaling by means of the fibroblast growth factor receptor 4/klotho beta receptor to activate cascades involved in hepatic lipogenesis, fatty acid oxidation, and insulin sensitivity. Emerging evidence of low circulating FGF19 levels in subsets of patients with pediatric and adult NAFLD demonstrates altered enterohepatic BA homeostasis in NAFLD.

Identifiers

PMID32258945
PMCPMC7109338
OpenAlexW3005127950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.